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Context: The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6Months (FREEDOM)
extension is evaluating the long-term efficacy and safety of denosumab for up to 10 years.
Objective: The objective of the study was to report results from the first 3 years of the extension,
representing up to 6 years of denosumab exposure.
Design, Setting, and Participants: Thiswas amulticenter, international, open-label study of 4550women.
Intervention:Women from the FREEDOMdenosumab group received 3more years of denosumab
for a total of 6 years (long-term) and women from the FREEDOM placebo group received 3 years
of denosumab (crossover).
Main Outcome Measures: Bone turnover markers (BTMs), bone mineral density (BMD), fracture,
and safety data are reported.
Results: Reductions in BTMs were maintained (long-term) or achieved rapidly (crossover) after
denosumab administration. In the long-term group, BMD further increased for cumulative 6-year
gains of 15.2% (lumbar spine) and 7.5% (total hip). During the first 3 years of denosumab treat-
ment, the crossover group had significant gains in lumbar spine (9.4%) and total hip (4.8%) BMD,
similar to the long-term group during the 3-year FREEDOM trial. In the long-term group, fracture
incidences remained lowandbelowtheratesprojectedforavirtualplacebocohort. In thecrossover
group, 3-year incidences of new vertebral and nonvertebral fractures were similar to those of the
FREEDOM denosumab group. Incidence rates of adverse events did not increase over time. Six
participants hadevents of osteonecrosis of the jawconfirmedbyadjudication.Oneparticipanthad
a fracture adjudicated as consistent with atypical femoral fracture.
Conclusion:Denosumab treatment for 6 years remainedwell tolerated,maintained reduced bone
turnover, and continued to increase BMD. Fracture incidence remained low. (J Clin Endocrinol
Metab 98: 4483–4492, 2013)
Receptor activator of nuclear factor-B ligand(RANKL) plays an essential role in mediating bone
resorption through osteoclast formation, function, and
survival (1, 2). After menopause, increased RANKL re-
sults in increased bone resorption and bone loss, which
can lead to osteoporosis (3), a condition characterized by
compromised bone strength and increased risk of fracture
(4, 5).
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Denosumab is a fully humanmonoclonal antibody that
binds with high specificity to human RANKL (6, 7),
thereby reducing osteoclast number and activity and de-
creasing bone resorption. In postmenopausalwomenwith
osteoporosis, denosumab significantly reduced bone turn-
over markers (BTMs), increased bone mineral density
(BMD), and reducednewvertebral (68%), hip (40%), and
nonvertebral (20%) fractures comparedwithplacebodur-
ing the pivotal 3-year Fracture Reduction Evaluation of
Denosumab in Osteoporosis Every 6 Months (FREEDOM)
trial (8).
Evaluating the long-term safety and efficacy of deno-
sumab is important because osteoporosis is a chronic dis-
ease requiring long-term treatment. A phase 2 dose-rang-
ing study demonstrated that up to 8 years of continued
denosumab treatment in a small group ofwomenwaswell
tolerated andassociatedwith continuedgains inBMDand
maintained reductions in BTMs (9). There is increasing
interest in the long-term effects of antiosteoporotic treat-
ments, and it is important to confirm key clinical trial
results. Therefore, in addition to the long-term phase 2
extension, the 3-year, phase 3 FREEDOM trial has been
extended for 7 additional years, during which all partic-
ipants receive open-label denosumab. We report here the
effects of denosumabonBTMs,BMD, safety, and fracture
rates for the first 3 years of the extension. Forwomen from
the FREEDOM placebo group who enrolled in the exten-
sion, these data (as the crossover group) provide a unique
opportunity for comparison with the original 3-year de-
nosumab FREEDOMobservations because these subjects
have now received 3 years of denosumab exposure. In
addition, for women from the FREEDOM denosumab
group who enrolled in the extension, these data (as the
long-term group) allow for evaluation of safety and effi-
cacy beyond 5 years of treatment.
Patients and Methods
Study design
The FREEDOM pivotal trial design (clinicaltrials.gov:
NCT00089791) and the extension design (clinicaltrials.gov:
NCT00523341)havebeendescribed inpreviouspublications (8,
10) and are summarized here. FREEDOM was a phase 3, mul-
ticenter, randomized, double-blind, placebo-controlled, 3-year
study conducted at 214 centers globally. Postmenopausal
women who enrolled had a lumbar spine or total hip BMD T-
score less than2.5at either locationand4.0or greater at both
locations and were 60–90 years old. Participants were random-
ized to receive placebo or 60mg denosumab (Prolia; Amgen Inc)
sc every 6months for 3 years andwere instructed to take calcium
(1 g) and vitamin D (400 IU) daily. All women who com-
pleted the FREEDOM trial [ie, completed their 3 y visit and did
not discontinue the investigational product (IP)] anddidnotmiss
more than one dose of IPwere eligible to enter the extension. The
extension was originally planned for 2 years but was subse-
quently extended to 7 years. At the end of 2 years, participants
consented again to continue for the additional 5 years. During
the extension period, all participants are scheduled to receive
denosumab 60mg sc every 6months (1mo)with daily calcium
andvitaminD.The study is ongoingandannual/preplanneddata
analyses are performedaspart of continuingpharmacovigilance.
The data reported here include the first 3 years of the extension,
representing up to 6 years of denosumab exposure for the long-
term group.
Representatives of the sponsor designed the study in collab-
oration with investigators and conducted the statistical analyses
according to a prespecified plan. The study protocol was ap-
proved by an institutional review board or ethics committee for
each site. Participants provided written informed consent. All
authorshadaccess to thedata, participated indraftingor revising
the manuscript, approved the final version for submission, and
take responsibility for the integrity of the analysis.
Study procedures
During the extension, study visits are scheduled at baseline
(corresponding to the end of the FREEDOM trial) and every 6
months for 7 years.
Measurements of serumC-terminal telopeptide of type 1 col-
lagen (CTX; Nordic Bioscience Diagnostics A/S) and procolla-
gen type1N-terminal propeptide (P1NP;OrionDiagnosticaOy)
were determinedusingovernight fasting serumsamples collected
from a subset of women who participated in the FREEDOM
BTM substudy and continued in the extension. To increase the
sample size of the BTM substudy, the protocol was amended to
include additional participants at year 2 of the extension, and
evaluation of these additional participants began at year 3 of the
extension. Subsequent to the publication of the data from the
first 2 years of the extension (10), additional samples for P1NP
from the second year were identified in storage by the central
laboratory. P1NP levels were measured in these samples and the
data have been included in the current analysis. Undetectable
values were imputed using the corresponding assay’s established
lower limit of detection value (CTX, 0.049 ng/mL; PINP, 10
g/L).
BMD measurements were performed by dual-energy x-ray
absorptiometry at the lumbar spine and proximal femur (all
women) and at the forearm (subset ofwomen) at extension base-
line and years 1, 2, and 3.
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Vertebral fractures were identified by a central facility (Sy-
narc Inc) using the Genant semiquantitative grading scale (11)
using thoracic and lumbar lateral radiographs obtained at ex-
tension baseline, year 2, and year 3. Prevalent vertebral fractures
at baseline and new vertebral fractureswere defined as described
previously (10). Clinical and nonvertebral fractures required
confirmation by a radiologist’s report or diagnostic imaging and
were documented as they occurred.
Subjects were queried about adverse events (AEs), clinical
fracture information, and concomitantmedications by study site
staff every 3 months. Each potential case of osteonecrosis of the
jaw (ONJ) was reviewed by an independent, blinded, external
adjudication committee, as described previously (12).
An adjudication process was initiated during year 6 to review
potential cases of atypical femoral fracture. Available x-ray im-
ages of femoral fractures that occurred at any time between base-
line and year 3 of the extensionwere retrospectively reviewed by
a panel at the central radiographic vendor site (Synarc Inc). Only
themajor criteria establishedby theASBMR2010TaskForce for
Atypical Subtrochanteric andDiaphysealFemoralFractures (13)
were used for adjudication by this panel: fracture location (sub-
trochanteric or femur diaphysis); fracture type (noncommi-
nuted, simple transverse, or short oblique); no or minimal trau-
ma; and the absence of any evidence of malignancy, prosthesis,
pins, or other hardware at or near the fracture site prior to the
fracture event. A finding of indeterminate was not permitted.
Statistical analyses
Theprimaryobjective of the extension is todescribe the safety
and tolerability of denosumab. Secondary objectives include
evaluation of the changes in BTMs and BMD and the incidence
of vertebral and nonvertebral fractures.
Safety analyses included participants who received one or
more doses of investigational product. Treatment groups were
defined by the original randomized assignments in FREEDOM.
For consistency with our prior report of the FREEDOM exten-
sion data (10), the Medical Dictionary for Regulatory Author-
ities version 13.0 was used to code and report AEs for this pub-
lication. The analyses ofAEs included exposure-adjusted subject
incidence rates and were descriptive. A selected group of serious
AEs/AEs are reported, consistent with the primary FREEDOM
publication (8) and the first long-term follow-up report (10).
Analyses of BTM included participantswho received one ormore
doses of investigational product in the extension and had observed
values at the time points of interest. Results are presented as actual
valuesandcorrespondtomediansandinterquartileranges.Analysesof
BMD percentage change from baseline were conducted as described
previously (10), required observed values at FREEDOMbaseline and
thetimepointsofinterest,andarepresentedasleastsquaresmeanswith
95% confidence intervals.
Crude subject incidence rates for new vertebral fracture and
new and worsening vertebral fracture were calculated and
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Figure 1. Disposition of all participants. All women who completed FREEDOM (ie, completed their 3 y visit, did not discontinue IP, and did not
miss more than one dose) were eligible to participate in the FREEDOM extension. a, Two women who discontinued denosumab also entered the
extension in the long-term denosumab group.
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Kaplan-Meier estimates of the cumulative incidence of clinical
vertebral, all clinical, nonvertebral, major nonvertebral, and hip
fractures were calculated. Nonvertebral fractures included low-
trauma fragility fractures only, as defined previously (8). New
vertebral and nonvertebral fracture incidence rates were also
calculated for a per-protocol (PP) subset and a modified
per-protocol (MPP) subset, both of which were prespecified.
Both subsets included participants whowere compliant with the
protocol (characterized by the nonviolation of any of the impor-
tant protocol deviations). TheMPP subset further excluded sub-
jectswhomissed twoormore (not necessarily consecutive) doses
of denosumab during the extension.
Because there was no placebo group in the extension, a sim-
ulation method developed for such an extension study design
(14) was used to estimate expected fracture rates in a hypothet-
ical cohort of placebo controls (virtual twin). As described pre-
viously, this modeled fracture risk for a theoretical placebo-
treated population matched to actual study participants with
regard to characteristics that were predictive of fracture risk in
the participants in the original FREEDOM placebo group (10).
Protocol-specified exploratory analyses were carried out com-
paring the model group’s estimated lumbar spine and nonver-
tebral fracture rateswith those observed in the treatment groups.
Estimates of the relative risks (RRs) and their respective boot-
strap 95% confidence intervals were calculated.
Fracture and safety data from all women enrolled in
FREEDOM are summarized in this manuscript to allow for
comparison with the 3-year extension results. For BTMs and
BMD, data from women enrolled in the extension are
presented.
Results
There were 7808 participants enrolled in the FREEDOM
pivotal trial (Figure 1).Of these, 5928 (76%)were eligible
for enrollment in the extensionand4550 (2343 long-term,
2207 crossover) enrolled (77%). By the end of the third
year, 78% (3547) of those enrolled remained on study.
Theproportionof participantswhodiscontinued from the
studyoverall and, for each reason,was similar between the
long-term and crossover groups. The baseline character-
istics for these groups at both the FREEDOM and exten-
sion baseline are shown in Table 1. Efficacy and safety
data from the long-term and crossover groups are de-
scribed separately below.
Long-term denosumab group
BTMs and BMD
Concentrations of serumCTXandP1NPare shown for
women in the BTM subset (Figure 2). After the first ex-
tension dose (the seventh dose of denosumab), median
values for the bone resorption marker CTX were 0.049
ng/mLatday10and0.131ng/mLatmonth6.For thebone
formationmarker P1NP,median valueswere 19.0g/L at
day 10 and 13.0 g/L at month 6. These results were con-
sistent with those observed after the first dose of deno-
sumab during the parent study. Throughout the 6 years of
the continued denosumab treatment, the median BTM
values remained below the median values observed at
FREEDOM baseline.
During the first 3 years of the extension, continued
increases in BMD occurred with long-term denosumab
treatment (4.9% lumbar spine; 1.8% total hip; 1.7% fem-
oral neck; 0.6%1/3 radius) for cumulative 6-year gains of
Table 1. Baseline Characteristics
Long-Term Denosumab Extension
Participants (n  2343)
Crossover Denosumab Extension
Participants (n  2207)
FREEDOM Baseline Extension Baseline FREEDOM Baseline Extension Baseline
Age, y 71.9 (5.0) 74.9 (5.0) 71.8 (5.1) 74.8 (5.1)
Age groups, n, %
65 2209 (94.3) 2294 (97.9) 2067 (93.7) 2149 (97.4)
 75 662 (28.3) 1258 (53.7) 624 (28.3) 1151 (52.2)
Years since menopause 23.7 (7.3) 26.7 (7.3) 23.7 (7.4) 26.7 (7.4)
Prevalent vertebral
fractures, n, %
559 (23.9) 573 (24.5) 485 (22.0) 551 (25.0)
Prevalent nonvertebral
fractures at age
55, n, %
702 (30.0) 780 (33.3) 651 (29.5) 754 (34.2)
Lumbar spine BMD
T-score
2.83 (0.67) 2.14 (0.80) 2.84 (0.68) 2.81 (0.75)
Total hip BMD T-score 1.85 (0.79) 1.50 (0.79) 1.85 (0.79) 1.93 (0.80)
CTX, ng/mL, median
(Q1, Q3)a
0.505 (0.357, 0.700) 0.182 (0.086, 0.555) 0.555 (0.420, 0.661) 0.568 (0.426, 0.728)
P1NP, g/L, median
(Q1, Q3)a
46.2 (31.5, 56.8) 17.3 (10.3, 26.0) 55.8 (42.5, 65.6) 48.8 (35.0, 67.6)
Abbreviations: n number of subjects enrolled in the extension; Q, quartile. Data are means with SD unless otherwise noted.
a Data are from subjects who were included in the BTM substudy.
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15.2% (lumbar spine), 7.5% (total hip), 6.7% (femoral
neck), and 2.7% (1/3 radius) (Figure 3).
Fractures
The incidence of newvertebral fractures during the first
3 years of the extension for the long-termgroupwas3.5%.
Similar rates were obtained for the prespecified PP (3.4%)
and MPP (2.9%) subsets. These rates were below those
observed in the parent trial placebo group (7.2%) (Figure
4A). They also were below the estimated fracture rates
expected had the denosumab participants who enrolled in
the extension receivedplacebo for6years [virtual placebo;
6.3%; RR 0.56 (0.39–0.78)]. Additionally, the incidence
of new and worsening vertebral (3.7%), clinical vertebral
(0.6%), and all clinical (4.4%) fractures with long-term
denosumab treatment (years 4–6) remained low and be-
low those observed in the parent trial placebo group
(7.3%, 2.6%, and 10.2%, respectively; Table 2).
For nonvertebral fractures, the 3-year incidence for the
long-term group during the extension was 3.8%. Similar
results were obtained for the PP (3.7%) and MPP (3.3%)
subsets. These rates were below those observed in the
FREEDOM denosumab (6.5%) and placebo (8.0%)
groups (Figure 4B). They also were below the estimated
fracture rate for the virtual placebo group [7.5%;RR0.50
(0.36–0.69)]. The incidence rates of major nonvertebral
(2.9%) and hip (0.4%) fractures with long-term deno-
sumab treatment (years 4–6) were below those observed
in the parent trial placebo group (6.4% and 1.2%, respec-
tively) and the parent trial denosumab group (5.2% and
0.7%, respectively; Table 2). The most common nonver-
tebral fracture sites in the long-term group during the first
3 years in the extension were wrist (distal ulna and distal
radius; n 31), rib (n 11), hip (n 9), and ankle (n
9) (n is the number of affected women).
Adverse events
The subject incidence rates per100 subject-years for all,
serious, and fatal AEs in the long-term group during the
extension were similar to or lower than those in the pla-
cebo anddenosumab groups during the parent trial (Table
3). The exposure-adjusted incidence rates of malignancy
(1.8 in FREEDOM and 1.9 in the extension period) and
infections (29.3 in FREEDOM and 23.4 in the extension
period) remained low and showed no trend toward in-
creases over time. The most commonly reported (0.1
events per 100 subject-years) malignancy AEs in the long-
term group during the extension were basal cell carci-
noma, breast cancer, colon cancer, and lung neoplasm
(0.5, 0.2, 0.1, and 0.1 events per 100 subject-years,
respectively).
Onemidshaft andone subtrochanteric femoral fracture
occurred in the long-term group during the first 3 years of
the extension. Bothwere sent for adjudication and neither
casewasdetermined tobe consistentwith atypical femoral
fracture.
Four oral events in the long-term group were adjudi-
cated as consistent withONJ during the first 3 years of the
extension. These cases occurred after the participants re-
ceived their 11th (two participants) or 12th (two partici-
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Figure 2. Concentrations of the bone turnover markers serum CTX (A) and serum P1NP (B). Data are medians and interquartile ranges. Time
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pants) doses of denosumab. Two of these participants dis-
continued denosumab therapy and the other two have
continued therapy. All four of the lesions have healedwith
appropriate treatment.
Crossover denosumab group
BTMs and BMD
Concentrations of serumCTXandP1NPare shown for
women in the BTM subset (Figure 2). After the first dose
of denosumab in the crossover group, there was a rapid
and marked reduction in median serum CTX reaching
0.049 ng/mL at day 10 and 0.092 ng/mL at month 6. For
the bone formation marker P1NP, median values were
56.0 g/L at day 10 and 13.0 g/L at month 6. These
results were consistent with those observed after the first
dose of denosumab during the parent study.
The crossover group had significant gains in BMD at
the lumbar spine (9.4%), total hip (4.8%), femoral neck
(4.0%), and 1/3 radius (1.2%) during the first 3 years of
denosumab treatment during the extension, similar to
those observed in the long-term denosumab group dur-
ing the first 3 years of FREEDOM (lumbar spine,
10.1%; total hip, 5.7%; femoral neck, 4.9%; 1/3 radius,
2.2%; Figure 3).
Fractures
The incidence of newvertebral fractures during the first
3 years of denosumab treatment in the extension for the
crossover group was 2.8%. Similar results were obtained
for the prespecified PP (2.9%) and MPP (2.9%) subsets.
These rateswere similar to the2.3%observed in the3-year
parent trial for the group that received denosumab and
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well below the 7.2% observed in the parent trial placebo
group (Figure 4C). They also were below the estimated
fracture rate for the virtual placebo group [6.1%;RR0.46
(0.31–0.67)]. The incidence of new and worsening verte-
bral (3.0%), clinical vertebral (0.3%), and all clinical
(5.9%) fractures with crossover denosumab treatment
(years 4–6) remained lowandbelow those observed in the
parent trial placebo group (7.3%, 2.6%, and 10.2%, re-
spectively; Table 2).
For nonvertebral fractures, the 3-year incidence for the
crossover group during the extension was 5.6%. Similar
results were obtained for the prespecified PP (5.4%) and
MPP (5.4%) subsets. These rates compare favorably with
those observed in the FREEDOMdenosumab (6.5%) and
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Figure 4. Incidence of new vertebral fractures (A and C) and nonvertebral fractures (B and D). Solid bars represent actual data collected and
dashed bars represent virtual placebo data. Percentages for new vertebral fractures are crude incidence and percentages for nonvertebral fractures
are Kaplan-Meier estimates. Error bars correspond to 95% confidence intervals.
Table 2. Fracture Incidence
Placebo Denosumab
FREEDOM
Years 1–3
FREEDOM
Years 1–3
Extension Long-Term
Years 4–6
Extension
Crossover Years 4–6
New and worsening vertebral 7.3% 2.4% 3.7% 3.0%
Clinical vertebral 2.6% 0.8% 0.6% 0.3%
All clinical 10.2% 7.2% 4.4% 5.9%
Major nonvertebrala 6.4% 5.2% 2.9% 4.3%
Hip 1.2% 0.7% 0.4% 0.7%
Percentages for new and worsening vertebral fractures are crude incidence. Percentages for clinical vertebral, all clinical, major nonvertebral, and
hip fractures are Kaplan-Meier estimates.
a Includes a subset of nonvertebral fractures including pelvis, distal femur (whole femur except proximal), proximal tibia, ribs, proximal humerus,
forearm, and hip.
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placebo (8.0%) groups (Figure 4D). They alsowere below
the estimated fracture rate for the virtual placebo group
[7.5%; RR 0.74 (0.54–0.99)]. The incidence of major
nonvertebral (4.3%) and hip (0.7%) fractures with cross-
over denosumab treatment (years 4–6) remained low and
below those observed in the parent trial placebo group
(6.4% and 1.2%, respectively; Table 2). The most com-
mon nonvertebral fracture sites in the crossover group
during the first 3 years in the extension were wrist (distal
ulna and distal radius; n  49), ankle (n  15), hip (n 
14), humerus (n  9), and foot (n  9).
Adverse events
During the first 3 years of the extension period, the
subject incidence rates of all, serious, and fatal AEs in the
crossover group were similar to or lower than those re-
ported by the FREEDOMplacebo anddenosumab groups
(Table 3). For example, the exposure-adjusted incidence
rates ofmalignancywere 1.8 in FREEDOMand 1.8 in the
extension, and for infection, theywere29.3 inFREEDOM
and 25.0 in the extension. The most commonly reported
(0.1 events per 100 subject-years) malignancy adverse
events in the crossover group during the extension were
basal cell carcinoma and breast cancer (0.4 and 0.2 events
per 100 subject-years, respectively).
There were two midshaft femur fractures in the cross-
over group during the first 3 years of the extension. Both
were sent for adjudication and one was considered by the
panel to be consistent with atypical femoral fracture. It
occurred after the participant had received six doses of
denosumab. The fracture was treated by internal fixation
and a 12-week, postoperation x-ray showed healing and
callus. The participant has discontinued therapy.
During the first 3 yearsof the extensionperiod, twooral
events in the crossover group were adjudicated as consis-
tent withONJ. These cases occurred after the participants
received their third and fourth dose of denosumab, re-
spectively. One participant discontinued therapy and the
other continued to receive denosumab without further
oral events. Both lesions have healed with appropriate
treatment.
Discussion
In theFREEDOMtrial, denosumabwas shown to increase
BMD, reduce BTMs, and decrease the risk of new verte-
bral and nonvertebral fractures (8). The purposes of the
study extension are to evaluate the long-term safety and
efficacy of continued denosumab administration (long-
termgroup) in a large number of participants and to assess
the consistency of findings from 3 years of denosumab
treatment (crossover group) as compared with the parent
study.
For the long-term group that continued denosumab for
a total of 6 years, BTMs were maintained at lower than
pretreatment levels andBMDcontinued to increase.These
distinctive long-term effects on BMD confirm the results
of the extended phase 2 study (9) and are consistent with
the previously reported effects of denosumab on trabec-
ular and cortical bone structure (15–17). Evidently the
apparent differences from bisphosphonate effects reflect
the differences in biological mechanisms. However, ex-
actly how the differences in drug mechanism of action
result in the observed differences in structural effects re-
mains to be fully elucidated. Fracture incidence in the
long-term group remained low and below the rates re-
ported in the FREEDOM placebo group. New vertebral
and nonvertebral fracture rates were also lower than the
fracture rates that would have been expected if extension
Table 3. Exposure-Adjusted Subject Incidence of Adverse Events
Placebo Denosumab
FREEDOM
Years 1–3
(N  3883), Rate, n
FREEDOM
Years 1–3
(N  3879), Rate, n
Extension Long-Term
Years 4–6
(N  2343), Rate, n
Extension Crossover
Years 4–6
(N  2206), Rate, n
All adverse events 156.1 (3614) 154.3 (3598) 106.2 (2067) 104.2 (1944)
Infections 30.7 (2113) 29.3 (2052) 23.4 (1070) 25.0 (1054)
Malignancies 1.6 (167) 1.8 (187) 1.9 (120) 1.8 (108)
Eczema 0.6 (67) 1.1 (119) 1.0 (65) 1.0 (57)
Hypocalcemia 0.1 (3) 0 0.1 (1) 0.1 (6)
Pancreatitis 0.1 (3) 0.1 (7) 0.1 (4a) 0.1 (2)
Serious adverse events 10.4 (974) 10.6 (1002) 10.6 (597) 10.9 (573)
Infections 1.3 (134) 1.5 (160) 1.3 (82) 1.4 (81)
Cellulitis or erysipelas 0.1 (1) 0.1 (12) 0.1 (5) 0.1 (1)
Fatal adverse events 0.8 (90) 0.6 (70) 0.7 (45) 0.7 (41)
Abbreviation: N, number of subjects who received one or more doses of IP; n, total number of subjects with an adverse event. Treatment groups
are based on the original randomized treatments received in FREEDOM. All subjects in the extension are receiving denosumab. The rate is the
exposure-adjusted subject incidence per 100 subject-years. Adverse events were coded using MedDRA version 13.0.
a Previously reported as 5; one case subsequently was determined to be a coding error.
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participants had received placebo, as estimatedwith a pre-
viously reported methodology (14). As discussed previ-
ously (10), this methodology is improved from a previous
osteoporosis study (18), not only in the sophistication of
the model but also in the use of data from the placebo
group of the same trial rather than a different population.
These observations are consistent with a 6-year mainte-
nance of effect by denosumab to reduce fractures.
A main objective of the extension was to further char-
acterize the safety of denosumab. Importantly, the subject
incidence rates of adverse events reported by participants
in the long-term group during the first 3 years of the ex-
tensionwere similar to or lower than those reported by the
FREEDOM placebo and denosumab groups. There was
no evidence of increased frequency of any specific event,
including malignancy and infections (including erysipelas
and cellulitis), despite the fact that the participants were
aging. Cases consistent with atypical femoral fracture and
ONJ have been observed in patients receiving denosumab
in this study, but the incidence remains low.
Because the cross-over group was treated with deno-
sumab for 3 years during the extension, therewas a unique
opportunity to compare these efficacy and safety results
with those obtained during the 3 years of denosumab
treatment in the parent trial. The data obtained were con-
sistent with FREEDOM observations: rapid and marked
reduction in BTMs, large increases in BMD, low fracture
rates, and a favorable benefit/risk profile. These data pro-
vide further supportive evidence for the consistency of re-
sults obtained with denosumab treatment.
The ultimate objective of osteoporosis treatment is the
reduction of fractures. Although this study did not have a
long-term placebo group, it is particularly noteworthy
that the rates of all fractures during the first 3 years of the
extension, for both the long-term and crossover deno-
sumab groups, were similar to or lower than the 3-year
rates observed during the parent trial for the denosumab
group. Interestingly, the rate of new vertebral fractures in
the crossover group was similar to that observed in the
extension long-term group. For nonvertebral fractures,
the rate in the crossover group was similar to that seen in
the denosumab group during the parent trial, whereas the
rate in the long-term group appears to have declined fur-
ther. The comparisons with the virtual placebo model are
consistent with these findings.
It was recently reported that gains in total hip BMD
predict a considerable proportion of the fracture risk re-
duction observedwith denosumab in the parent trial (15),
suggesting thepossibility of using change in total hipBMD
as a predictor for the effect of denosumab treatment on
fracture risk. With this in mind, the continued gains in
total hip BMD observed over 6 years of treatment with
denosumab in this extension study are encouraging.
One inherent limitation of the study is that not all qual-
ified FREEDOMparticipants enrolled in the extension, so
long-term efficacy and safety observations were limited to
those who were eligible and chose to participate. In addi-
tion, the open-label design of the study and the lack of a
continuing placebo group precluded direct comparisons
of results from denosumab-treated participants and pla-
cebo-treated participants for all measures. A virtual pla-
cebo (virtual twin)modelwas used to estimate the fracture
risk for a placebo-treated population otherwise similar to
the denosumab-treated subjects.
In summary, in the ongoing extension to the FREE-
DOMtrial, 6 years of denosumab treatment of postmeno-
pausal womenwith osteoporosis was associated with sus-
tained but not progressive decreases in bone turnover,
continued increases inBMD,andmaintenanceof low frac-
ture rates. Efficacy data from the cross-over group were
consistent with observations from the 3 years of the orig-
inal FREEDOM trial. There was no apparent increase in
the risk of AEs with extended exposure or with cross-over
from the placebo group.
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